Nxera Pharma Co., Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Chris Cargill
- Full Time Employees
- 382
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Midtown East Tokyo Japan 107-0052
- IPO Date
- Jul 28, 2004
- Website
- nxera.life
- Similar Companies
- Business
- Nxera Pharma Co., Ltd. is a biopharmaceutical enterprise engaged in the discovery, development, and commercialization of pharmaceutical innovations across Japan, Switzerland, the United States, Bermuda, and the United Kingdom. The company, formerly known as Sosei Heptares, rebranded to Nxera Pharma in April 2024, signifying its ambition to pioneer the next generation of medical treatments globally. Its commercial portfolio includes PIVLAZ™ (clazosentan) for the prevention of cerebral vasospasm following aneurysmal subarachnoid hemorrhage, and QUVIVIQ™ (daridorexant) for addressing insomnia, which launched in Japan in late 2024. The revenue model combines product sales, particularly within Japan and the broader APAC region, with significant milestone and royalty payments from its numerous alliances with major global pharmaceutical firms. Nxera Pharma maintains a robust pipeline, encompassing over 30 programs from early discovery through late-stage clinical trials, driven by its proprietary NxWave™ platform focusing on G Protein-Coupled Receptors (GPCRs) for structure-based drug design. A recent strategic pivot in November 2025 has directed approximately 80% of its pipeline investment towards obesity and metabolic disorders, an area of significant unmet need, while non-priority assets are being evaluated for partnerships or discontinuation. The newly unveiled proprietary pipeline in this domain features an oral small molecule GLP-1 agonist alongside six additional programs targeting GIP, Amylin, and Apelin receptors, designed to address long-term weight management and associated metabolic conditions. Key development candidates also include NBI-'568, a muscarinic agonist, currently in Phase 3 trials through a collaboration with Neurocrine Biosciences, and HTL0039732, an immuno-oncology agent, which has entered Phase 2a clinical studies and demonstrated encouraging early efficacy in Phase 1. The company fosters extensive strategic collaborations, including multi-target discovery agreements with AbbVie for neurological diseases, having recently achieved multiple R&D milestones, and with Eli Lilly for diabetes and metabolic disorders. Further partnerships involve PrecisionLife for target identification in autoimmune disorders, Antiverse for AI-driven antibody therapeutics, and Viatris for cenerimod commercialization in Japan and APAC. Nxera Pharma Co., Ltd. was established in 1990 and operates from its headquarters in Tokyo, Japan.
Company News
Nxera Pharma Co., Ltd. (SOLTF) Q2 2026 Earnings Call Transcript
Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery
Nxera's Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea
Nxera's President & CEO to Participate in a ‘Fireside Chat' at the Jefferies New York Healthcare Conference 2026
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Nxera Pharma Co., Ltd. (OTCMKTS:SOLTF) Short Interest Update
Nxera Pharma's QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea
Nxera Pharma Co., Ltd. (SOLTF) Q4 2025 Earnings Call Transcript
Nxera Pharma Proposes Changes to its Board of Directors
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
Nxera Pharma Co., Ltd. (SOLTF) Presents at 44th Annual J.P.